Table 2 Circle of willis anatomy and outcomes
|  | All BCVIs n = 561 % (n/N) | Circle of Willis Anomaly 16.6% (93/561) % (95% CI) | Circle of Willis Normal 83.4% (468/561) % (95% CI) | p | Anterior Anomaly 83.9% (78/93) % (95% CI) | Posterior Anomaly 16.1% (15/93) % (95% CI) | p |  |
|---|---|---|---|---|---|---|---|---|
Any Stroke | 5.4% (29/561) | 9.7% (5.2–17.4) | 4.3% (2.8–6.5) | 0.04 | 9.0% (4.4–17.4) | 13.3% (3.7–37.9) | 0.63 |  |
Hemorrhagic Stroke | 0.7% (4/561) | 2.2% (0.6–7.5) | 0.4% (0.1–1.5) | 0.13 | 1.3% (0.2–6.9) | 6.7% (1.2–29.8) | 0.19 |  |
Ischemic Stroke (IS) | 4.5% (25/561) | 7.5% (3.7–14.7) | 3.9% (2.5-6.0) | 0.16 | 7.7% (3.6–15.8) | 6.7% (1.2–29.8) | > 0.99 |  |
Any Bleeding Complication | 47.3% (44/561) | 47.3% (37.5–57.4) | 29.5% (25.5–33.8) | 0.001 | 47.4% (36.7–58.4) | 41.7% (19.3–68.1) | > 0.99 |  |
ICH | 24.1% (135/561) | 37.6% (28.5–47.8) | 21.4% (17.9–25.3) | 0.001 | 41.0% (30.8–52.1) | 20.0% (7.1–45.2) | 0.12 |  |
IS in Patients with an ICH | 2.2% (2/135) | 5.7% (1.6–18.6) | 1.0% (0.2–5.5) | 0.16 | 6.3% (1.7, 20.2) | 0% (0-16.7) | > 0.99 |  |
Other Clinically Significant Bleed (CSB) | 16.0% (72/451) | 29.0% (19.6–40.6) | 13.6% (10.5–17.4) | 0.001 | 26.8% (17.0-39.6) | 38.5% (17.7–64.4) | 0.50 |  |
IS in Patients with Other CSB | 19.4% (14/72) | 25.0% (11.2–48.9) | 17.3% (9.4–29.7) | 0.51 | 26.7% (10.9–52.0) | 20.0% (3.6–62.5) | > 0.99 |  |
Antithrombotic Administered | 89.8% (503) | 91.4% (83.0-95.6) | 89.5% (86.4–92.0) | 0.70 | 92.3% (84.2–96.4) | 86.7% (62.1–96.3) | 0.61 |  |
IS in those Given Antithrombotics | 4.6% (23/503) | 7.1% (3.3–14.6) | 4.1% (2.6–6.4) | 0.25 | 6.9% (3.0-15.3) | 7.7% (1.4–33.3) | > 0.99 |  |
IS in those Not Given Antithrombotics | 3.5% (2/57) | 12.5% (2.2–47.1) | 2.0% (0.4–10.7) | 0.26 | 16.7% (3.0-56.4) | 0% (0–25.0) | > 0.99 |  |
ICH in those Given Antithrombotics | 21.9% (110/503) | 37.7% (28.1–48.3) | 18.7% (15.2–22.7) | 0.0003 | 41.0% (30.8–52.1) | 15.4% (4.3–42.2) | 0.12 |  |
ICH in those Not Given Antithrombotics | 42.1% (24/57) | 37.5% (13.7–69.4) | 42.9% (30.0-56.7) | > 0.99 | 50.0% (9.5–90.6) | 33.3% (9.7–70.0) | > 0.99 |  |
Antithrombotics Interrupted | 31.2% (157/503) | 26.5% (18.2–36.9) | 32.2% (27.9–36.9) | 0.40 | 24.7% (15.8–35.5) | 38.5% (17.7–64.4) | 0.32 |  |
IS in those with Antithrombotics Interrupted | 3.2% (5/157) | 13.0% (4.5–32.1) | 1.5% (0.4–5.3) | 0.02 | 11.1% (3.1–32.8) | 20.0% (3.6–62.5) | 0.54 |  |
IS in those without Antithrombotic Interrupted | 5.2% (16/368) | 4.6% (1.6, 1.7) | 5.3% (3.3–8.4) | > 0.99 | 5.5% (1.9 14.9) | 0% (0–5.0) | > 0.99 |  |
CSB Before Antithrombotics Administered | 5.6% (28/503) | 14.0% (9.2–24.4) | 3.2% (2.2–5.8) | < 0.0001 | 15.3% (8.8–25.3) | 15.4% (4.3–42.2) | > 0.99 |  |
IS in those with Bleed Before Antithrombotics | 21.4% (6/28) | 7.7% (1.4–33.3) | 33.3% (15.2–58.3) | 0.17 | 9.1% (1.6–37.7) | 0% (0–25.0) | > 0.99 |  |
CSB After Antithrombotics Administered | 7.2% (37/503) | 7.1% (3.3–14.6) | 7.2% (5.1–10.1) | 0.70 | 4.2% (1.4–11.6) | 23.1% (8.2–50.3) | 0.04 |  |
IS in those with Bleed After Antithrombotics | 24.3% (9/37) | 57.1% (25.1–84.2) | 16.7% (7.3–33.6) | 0.045 | 75.0% (30.1–95.4) | 33.3% (6.2–79.2) | 0.49 |  |
CSB Both Before and After Administered | 1.4% (8/503) | 0% (0-3.2) | 1.7% (0.9–3.3) | 0.36 | 0% (0-0.6) | 0% (0-3.8) | N/A |  |
IS in those with Bleed Before and After | 0% (0/8) | 0% (0-3.2) | 0% (0-0.6) | N/A | 0% (0-0.6) | 0% (0-3.8) | N/A | Â |
HLOS, Median Days (IQR) | 7.0 (3.0, 13.1) | 7.0 (3.0, 14.0) | 7.0 (3.0, 13.0) | 0.66 | 8.0 (4.0, 14.0) | 5.0 (3.0, 8.0) | 0.052 | Â |
ICULOS, Median Days (IQR) | 3.0 (1.0, 7.0) | 4.0 (2.0, 8.0) | 3.0 (1.0, 7.0) | 0.16 | 5.0 (2.0, 10.0) | 2.0 (0, 3.0) | 0.03 | Â |
Mortality | 7.3% (41/561) | 8.6% (4.4–16.1) | 7.1% (5.1–9.7) | 0.66 | 7.7% (3.6–15.8) | 13.3% (3.7–37.9) | 0.61 |  |